Bristol Myers Squibb Company spent the past year laying out its plan for growth through the end of this decade as its three top-selling products lose exclusivity. While 2022 will be the first year that the company’s strategy is put to the test as Revlimid (lenalidomide) faces its first generic competition, the contribution of new product launches to Bristol’s revenue in 2021 suggests that plan is off to a good start.
BMS reported on 4 February that its full-year 2021 product sales totaled $46.4bn, up 9% from 2020, including $12bn in fourth quarter sales, up 8% from the year-ago period. The full-year total included $1
Three Launches In 2022
BMS anticipates approvals in the US this year for:
-
A fixed-dose combination of the LAG3 inhibitor relatlimab and the PD-1 inhibitor Opdivo in first-line treatment of melanoma with a 19 March PDUFA date (Also see "BMS’s Anti-LAG3 Drug Could Offer Safer Combo Partner To Opdivo Monotherapy Patients" - Scrip, 20 May, 2021.);
-
The allosteric myosin inhibitor mavacamten in obstructive hereditary cardiomyopathy with a 28 April action date (Also see "BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten" - Scrip, 5 October, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
